Tetrahydroquinazoline N-oxide derivatives inhibit reproduction of tick-borne and mosquito-borne flaviviruses
- PMID: 37138375
- DOI: 10.1002/ardp.202300027
Tetrahydroquinazoline N-oxide derivatives inhibit reproduction of tick-borne and mosquito-borne flaviviruses
Abstract
Tick-borne encephalitis virus (TBEV), yellow fever virus (YFV), and West Nile virus (WNV) are flaviviruses causing emerging arthropod-borne infections of a great public health concern. Clinically approved drugs are not available to complement or replace the existing vaccines, which do not provide sufficient coverage. Thus, the discovery and characterization of new antiflaviviral chemotypes would advance studies in this field. In this study, a series of tetrahydroquinazoline N-oxides was synthesized, and the antiviral activity of the compounds was assessed against TBEV, YFV, and WNV using the plaque reduction assay along with the cytotoxicity to the corresponding cell lines (porcine embryo kidney and Vero). Most of the studied compounds were active against TBEV (EC50 2 to 33 μM) and WNV (EC50 0.15 to 34 μM) and a few also demonstrated inhibitory activity against YFV (EC50 0.18 to 41 μM). To investigate the potential mechanism of action of the synthesized compounds, time-of-addition (TOA) experiments and virus yield reduction assays were performed for TBEV. The TOA studies suggested that the antiviral activity of the compounds should affect the early stages of the viral replication cycle after cell entry. Compounds with tetrahydroquinazoline N-oxide scaffold show a broad spectrum of activity against flaviviruses and represent a promising chemotype for antiviral drug discovery.
Keywords: West Nile virus; antivirals; tetrahydroquinazolines; tick-borne encephalitis virus; yellow fever virus.
© 2023 Deutsche Pharmazeutische Gesellschaft.
Similar articles
-
3-[N,N-Bis(sulfonyl)amino]isoxazolines with Spiro-Annulated or 1,2-Annulated Cyclooctane Rings Inhibit Reproduction of Tick-Borne Encephalitis, Yellow Fever, and West Nile Viruses.Int J Mol Sci. 2023 Jun 28;24(13):10758. doi: 10.3390/ijms241310758. Int J Mol Sci. 2023. PMID: 37445937 Free PMC article.
-
Antiviral activity of the adenosine analogue BCX4430 against West Nile virus and tick-borne flaviviruses.Antiviral Res. 2017 Jun;142:63-67. doi: 10.1016/j.antiviral.2017.03.012. Epub 2017 Mar 21. Antiviral Res. 2017. PMID: 28336346
-
Elongation of N6-benzyladenosine scaffold via Pd-catalyzed C-C bond formation leads to derivatives with antiflaviviral activity.Bioorg Med Chem. 2024 Jan 15;98:117552. doi: 10.1016/j.bmc.2023.117552. Epub 2023 Dec 10. Bioorg Med Chem. 2024. PMID: 38128296
-
Recent progress in West Nile virus diagnosis and vaccination.Vet Res. 2012 Mar 1;43(1):16. doi: 10.1186/1297-9716-43-16. Vet Res. 2012. PMID: 22380523 Free PMC article. Review.
-
Identifying Attenuating Mutations: Tools for a New Vaccine Design against Flaviviruses.Intervirology. 2017;60(1-2):8-18. doi: 10.1159/000479966. Epub 2017 Sep 5. Intervirology. 2017. PMID: 28869941 Review.
Cited by
-
3-[N,N-Bis(sulfonyl)amino]isoxazolines with Spiro-Annulated or 1,2-Annulated Cyclooctane Rings Inhibit Reproduction of Tick-Borne Encephalitis, Yellow Fever, and West Nile Viruses.Int J Mol Sci. 2023 Jun 28;24(13):10758. doi: 10.3390/ijms241310758. Int J Mol Sci. 2023. PMID: 37445937 Free PMC article.
References
REFERENCES
-
- T. C. Pierson, M. S. Diamond, Nat. Microbiol. 2020, 5, 796. https://doi.org/10.1038/s41564-020-0714-0
-
- T. C. Pierson, M. S. Diamond, Fields Virology, Lippincott Williams & Wilkins, Philadelphia 2013, p. 747.
-
- V. Sharma, M. Sharma, D. Dhull, Y. Sharma, S. Kaushik, S. Kaushik, Can. J. Microbiol. 2020, 66, 87. https://doi.org/10.1139/cjm-2019-0331
-
- Q. A. Ahmed, Z. A. Memish, Trop. Doct. 2017, 47, 92. https://doi.org/10.1177/0049475517699726
-
- D. Ruzek, T. Avšič Županc, J. Borde, A. Chrdle, L. Eyer, G. Karganova, I. Kholodilov, N. Knap, L. Kozlovskaya, A. Matveev, A. D. Miller, D. I. Osolodkin, A. K. Överby, N. Tikunova, S. Tkachev, J. Zajkowska, Antiviral Res. 2019, 164, 23. https://doi.org/10.1016/j.antiviral.2019.01.014
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical